MRG003安全性分析：2025最新研究数据

The safety profile was analyzed in this study. No additional safety risks were observed [16, 19]. In this study, the hematological toxicity of MRG003 was less severe compared to chemotherapy; the incidence of specific adverse events (AEs) of concern with MRG003 was 4.7%, and all have been resolved, except for one case of grade 2 idiopathic interstitial pneumonia which is still under recovery. Additionally, although most neurotoxicity AEs were grade 1-2 and the majority of adverse reactions could be managed with symptomatic treatment, neurotoxicity still requires close monitoring. Overall, MRG003 is safe and tolerable, with all adverse events being manageable.